AzTrials
AzTrials

AMLPhase 1NCT05740917

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

A Phase 1 study testing XZB-0004 in people with AML and MDS, run by Xuanzhu Biopharmaceutical Co., Ltd. at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is an open-label, multicenter Phase I study that will enroll patients with relapsed/refractory AML or MDS. Stage Ia and stage Ib are included in this study. Phase Ia is a single-agent dose-escalation study that enrolling R/R AML subjects to identify XZB-0004 monotherapy MTD (if any) and RP2D and evaluate its… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
AML, MDS
What is being tested?
XZB-0004
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
82 participants
Where
1 siteChina
Study dates
Feb 2023to Feb 2023
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Willing to sign written informed consent, able to communicate well with researchers and willing to comply with research regulations.
  • Both men and women can be at least 18 years old at the time of signing the informed consent form.
  • Expected survival ≥ 3 months.
  • The Eastern Cancer Collaboration (ECOG) Physical Fitness score is 0, 1 or 2.
  • Relapsed or refractory AML that meets the classification criteria of hematopoietic and lymphoid tissue tumors revised by the World Health Organization (WHO) in 2016 and is confirmed by bone marrow cell morphology (except acute promyelocytic leukemia) :
  • Criteria for the diagnosis of recurrent AML: recurrence of leukemia cells in peripheral blood after complete response (CR) or ≥5% of primitive cells in bone marrow (except for other causes such as bone marrow regeneration after consolidation chemotherapy) or extramedullary infiltration of leukemia cells.
Show all 24Show fewer
  • Diagnostic criteria for refractory AML:
  • age 18 - 60 one full year of life: Initial treatment cases that did not go into remission after 2 courses of treatment with the standard regimen (containing cytarabine and an anthracycline or anthracquinone); Patients who do not achieve remission after 1 cycle of standard regiments and cannot continue chemotherapy with standard regiments due to age, comorbidities, physical status, and/or adverse risk factors; Or CR after consolidation and intensive treatment, relapse within 12 months; Or recurred 12 months later but failed conventional chemotherapy (no PR or CR); Or two or more relapses; Or extramedullary leukemia persists.
  • Age \> 60 years old: Patients who cannot tolerate standard chemotherapy regiments due to age, comorbiditions, physical status, and/or adverse risk factors, or finances were treated with 4 cycles of demethylated drugs (e.g., decitabine or azactidine) and 2 cycles of low-dose chemotherapy ± demethylated drugs.
  • Relapsed or refractory MDS: Subjects diagnosed by bone marrow cell morphology and cytogenetics WHO (2016) revised classification of MDS as MDS with protocytosis (MDS-EB) :
  • Recurrent MDS: Complete response (CR), partial response (PR), or hematological improvement (HI) following at least one of the following responses according to the International Working Group 2006 (IWG 2006) evaluation criteria (see Appendix 7) : ① Bone marrow primitive cells recovered to the pre-treatment level, ② neutrophil absolute count (ANC) or platelet count (PLT) decreased by more than 50% compared with the optimal treatment, ③ hemoglobin (HGB) decreased by more than 15 g/L or depended on blood transfusion;
  • Refractory MDS: After adequate treatment (for example, demethylated drug treatment ≥4 cycles), patients meet the criteria of "disease stabilization", "failure", and "disease progression" according to the IWG 2006 efficacy evaluation criteria;
  • In addition, if drugs other than methylated drugs progress after treatment or are unable to tolerate toxicity (such as drug-related grade 3 or above liver and kidney toxicity during treatment leading to permanent drug withdrawal); The investigators determined that patients with no other appropriate treatment could also be enrolled.
  • Stage Ia: meet (1);
  • Stage Ib Group 1: meet (1);
  • Stage Ib Group 2: meet (2);
  • 6. Consent for bone marrow aspiration and/or biopsy during screening and treatment.
  • 7. Subject's white blood cell count is less than 30 × 109/L (treatment with hydroxyurea is allowed, but not allowed within 3 days prior to the first treatment with the study drug).
  • 8. Laboratory examination results during the screening period indicate that the subject has appropriate organ function (the following criteria should also be met) :
  • Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or endogenous creatinine clearance (CrCl) ≥ 50 mL/min/1.73 m2 as estimated by the Cockcroft-Gault formula (Appendix 2);
  • aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN (except liver infiltration of leukemia cells);
  • Serum total bilirubin (TBIL) ≤ 1.5 ULN (except liver infiltration of leukemia cells);
  • Normal or abnormal prothrombin time (PT) and activated partial thrombin time (APTT) had no clinical significance (APTT did not exceed the upper limit of normal for 10s, PT did not exceed the upper limit of normal for 3s);
  • 9. Women and men of reproductive age must agree, upon signing an informed consent form, to use effective contraceptive methods during the study period and within 6 months after the last dose of XZB-0004.

Who cannot join

  • Patients with a history of malignancies other than the disease under study within 5 years prior to initial administration of XZB-0004, except those that have been cured for at least 3 years prior to initial administration, such as thyroid carcinoma, cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ of the breast, etc.
  • XZB-0004 received systemic antitumor therapy, including chemotherapy, radiotherapy, antibodies, targeted therapy, investigational drugs, etc. within 2 weeks or 5 half-lives prior to initial administration.
  • XZB-0004 was treated with an H2 receptor inhibitor, proton pump inhibitor, or acid suppressor within 3 days prior to initial administration.
  • Adverse reactions caused by previous treatment did not recover to NCI-CTCAE V5.0 level or below (except hair loss and abnormal laboratory examination without clinical significance, etc.).
  • XZB-0004 received adoptive immune cell therapy, including chimeric antigen receptor T cells (CAR), within 12 weeks prior to initial administration.
  • Autologous hematopoietic stem cell transplantation less than half a year, allogeneic hematopoietic stem cell transplantation.
Show all 20Show fewer
  • Central nervous system leukemia or central nervous system (CNS) invasion.
  • Patients who had received major surgical treatment within 4 weeks prior to the initial administration of XZB-0004.
  • There are serious cardiovascular disease risk factors such as:
  • Chronic heart failure with heart function > Grade 2 (New York Heart Association NYHA scale);
  • If myocardial infarction occurs within 3 months before the first dose, the subject should discuss with the sponsor to confirm his eligibility if his ECG indicates a history of past myocardial infarction;
  • Uncontrolled cardiovascular disease, including unstable angina, clinically uncontrollable hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100 mmHg);
  • Corrected QTcF interval using Fridericia's formula (Appendix 2); 450msec (male) and \> 470msec (female).
  • Left ventricular ejection fraction (LVEF) \< 50%
  • Active infection is present.
  • Inability to take medications orally.
  • Suffering from active peptic ulcer, Crohn's disease, apparent vomiting, chronic diarrhea, intestinal obstruction, malabsorption, or other diseases known to affect drug absorption; Having difficulty swallowing or other conditions that severely affect drug absorption, such as having undergone a gastrectomy or enterectomy.
  • Active hepatitis B (HBsAg and/or HBcAb positive with HBV-DNA > 500IU/mL) or hepatitis C virus infection (anti-HCV positive with HCV-RNA positive) or human immunodeficiency virus (HIV) antibody positive or syphilis antibody positive.
  • Pregnant or lactating women.
  • There are other severe, acute or chronic medical or mental illnesses or laboratory abnormalities that, in the judgment of the investigator, may increase the risks associated with study participation or may interfere with the interpretation of the findings.

Trial locations and contacts

1 site in 1 country.

Xiujie Zhang contact

+86-13671737230

zhangxiujie@xuanzhubio.com

China1 site

  • Hematology Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, 300020

    Jianxiang Wang, +86-13821389157, wangjx@ihcams.ac.cn

Other trials in China

About this study

Official title: A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Initial Efficacy of XZB-0004 in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

This is an open-label, multicenter Phase I study that will enroll patients with relapsed/refractory AML or MDS. Stage Ia and stage Ib are included in this study. Phase Ia is a single-agent dose-escalation study that enrolling R/R AML subjects to identify XZB-0004 monotherapy MTD (if any) and RP2D and evaluate its safety and pharmacokinetic profile. Phase Ib will be an expanded study in R/R AML patients (group 1) and R/R MDS patients (group 2) at RP2D doses to further evaluate and determine the efficacy and safety of XZB-0004 in R/R AML or R/R MDS patients.

Conditions
AML, MDS
Being tested
XZB-0004
Keywords
XZB-0004, AXL inhibitor

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • XZB-0004Drug

    XZB-0004 orally Twice daily of every 28-day cycle

Study groups in NCT05740917
Study groupRoleWhat they receive
Part 1: XZB-0004ExperimentalNot described
Receives: Drug: XZB-0004

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum tolerated dose (MTD) (for Part 1)

    Determine MTD of XZB-0004

    Measured: 28 days following first dose of XZB-0004

  2. Overall Response Rate (ORR) (for Part 2)

    ORR is the proportion of subjects with CR or PR , based on RECIST v1.1.

    Measured: 2 years after first dose of XZB-0004

Secondary outcomes (2)

  1. Area under the concentration versus time curve of XZB-0004 in plasma (AUC)

    To determine the area under the plasma concentration time curve (AUC) of XZB-0004

    Measured: 2 months after first dose of XZB-0004

  2. Maximum plasma concentration (Cmax) of XZB-0004

    Cmax is the maximum observed plasma concentration in ng/mL

    Measured: 2 months after first dose of XZB-0004

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Feb 2023
  2. Study startFeb 2023 (estimated)
  3. Primary completionFeb 2023 (estimated)
  4. Study completionFeb 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
82 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05740917
Sponsor's protocol ID
XZB-0004-1002
Status last verified
Feb 2023
First submitted
13 Feb 2023
Last updated
23 Feb 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing XZB-0004 in people with AML and MDS, run by Xuanzhu Biopharmaceutical Co., Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Xiujie Zhang (+86-13671737230, zhangxiujie@xuanzhubio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum tolerated dose (MTD) (for Part 1) (time frame: 28 days following first dose of XZB-0004). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05740917.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in